
PODD
Insulet Corporation
Company Overview
| Mkt Cap | $20.84B | Price | $204.31 |
| Volume | 886.80K | Change | +0.00% |
| P/E Ratio | 49.8 | Open | $202.93 |
| Revenue | $2.1B | Prev Close | $204.31 |
| Net Income | $418.3M | 52W Range | $202.44 - $354.88 |
| Div Yield | N/A | Target | $355.17 |
| Overall | 35 | Value | 30 |
| Quality | 57 | Technical | 18 |
No chart data available
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News
RBC Capital Reaffirms Their Buy Rating on Insulet (PODD)
Vanguard S&P 500 ETF (VOO) Daily Update, 4/3/2026?
Why Is the SPY ETF Up Today, 4/2/2026?
Bracing for Stagflation? These 2 Stocks Offer Mouth-Watering Upside
Stagflation Watch: 3 Stocks Analysts Are Backing (PODD vs. CEG vs. WMT)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PODD | $204.31 | 0% | 886.80K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |